Daily Medication Pearl: Ertugliflozin (Steglatro)

Ertugliflozin (Steglatro) is a sodium glucose co-transporter 2 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Medication Pearl of the Day: Ertugliflozin (Steglatro)

Indication: Ertugliflozin (Steglatro) is a sodium glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Insight:

  • Dosing: Recommended starting dose is 5 mg once daily, taken in the morning, with or without food.
  • Dosage forms: Tablets 5 mg and 15 mg.
  • Adverse events: The most common adverse reactions associated with ertugliflozin (incidence ≥ 5%) were female genital mycotic infections.
  • Mechanism of action: SGLT2 is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. Ertugliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, ertugliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.
  • Manufacturer: Merck

Source: LABEL (fda.gov)